Jiangsu Aidea Pharmaceutical Co., Ltd. (688488) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jiangsu Aidea Pharmaceutical Co., Ltd.

Why is Jiangsu Aidea Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0.38%

The company has been able to generate a Return on Capital Employed (avg) of 0.38% signifying low profitability per unit of total capital (equity and debt)

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of 16.75% and Operating profit at 12.38% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 0.68% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 16.75% and Operating profit at 12.38% over the last 5 years

With a growth in Net Profit of 101.52%, the company declared Very Positive results in Jun 26

The company has declared positive results for the last 6 consecutive quarters
INTEREST COVERAGE RATIO(Q) Highest at 842.89
ROCE(HY) Highest at -0.61%
OPERATING PROFIT(Q) Highest at CNY 35.4 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 11.04%, its profits have risen by 88.6%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jiangsu Aidea Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jiangsu Aidea Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Jiangsu Aidea Pharmaceutical Co., Ltd.

4.52%

0.39

60.47%

China Shanghai Composite

0.9%

0.22

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.75%

EBIT Growth (5y)

12.38%

EBIT to Interest (avg)

-28.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

0.33

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.39%

ROE (avg)

0.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.00

EV to EBIT

222.03

EV to EBITDA

74.29

EV to Capital Employed

4.33

EV to Sales

7.25

PEG Ratio

Dividend Yield

ROCE (Latest)

1.95%

ROE (Latest)

-1.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

INTEREST COVERAGE RATIO(Q)

Highest at 842.89

ROCE(HY)

Highest at -0.61%

OPERATING PROFIT(Q)

Highest at CNY 35.4 MM

PRE-TAX PROFIT(Q)

Highest at CNY 26.56 MM

NET PROFIT(Q)

Highest at CNY 19.65 MM

EPS(Q)

Highest at CNY 0.04

-3What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 7.69% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 30.01 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.96 times

Here's what is working for Jiangsu Aidea Pharmaceutical Co., Ltd.

Interest Coverage Ratio

Highest at 842.89 and Grown

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Pre-Tax Profit

At CNY 26.56 MM has Grown at 15,531.34%

over average net sales of the previous four periods of CNY 0.17 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 19.65 MM has Grown at 311.28%

over average net sales of the previous four periods of CNY -9.3 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Profit

Highest at CNY 35.4 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (CNY MM)

Pre-Tax Profit

Highest at CNY 26.56 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 19.65 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.04

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Here's what is not working for Jiangsu Aidea Pharmaceutical Co., Ltd.

Debt-Equity Ratio

Highest at 30.01 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 0.96 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 7.69% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading